Objective: To investigate the clinical impact of vancomycinresistant enterococci (VRE) colonization in patients with hematologic malignancies and associated risk factors.
Introduction
Children with cancer are at high risk of developing systemic infections by the microorganisms that colonize their own intestinal system [1, 2] . Vancomycin-resistant enterococci (VRE) are health care-associated opportunistic pathogens. Limited data exist on the incidence of subsequent VRE infection development among VRE-colonized pediatric cancer patients and associated risk factors, which were investigated in this study.
Materials and Methods
All patients admitted to the pediatric hematology/oncology ward were sampled within 48-72 h after admission and weekly thereafter as part of institutional rectal VRE surveillance. An infection control nurse assigned by the Hospital Infection Control Committee (HICC) prospectively tracked the results of rectal surveillance and all health care-associated infections occurring in the hematology/oncology ward. VRE-colonized and VRE-infected patients were identified from the HICC surveillance database retrospectively. Detailed clinical and laboratory features of these patients were collected from their medical records. The overall rate of VRE colonization and the subsequent infection occurrence throughout the study period were determined. To identify the risk factors associated with VRE infection occurrence in a colonized patient, a retrospective case-control study was performed. Patients were defined as VREcolonized (VRE-C) when the culture of the rectal swab yielded VRE in the absence of any clinical specimens positive for VRE [3] . Systemic VRE infection (VRE-I) was defined as isolation of VRE from a clinical specimen together with signs and symptoms of infection. Statistical analysis was performed with SPSS 21.0 for Windows. Parameters were compared between groups with the chi-square test, Fisher exact test, or Mann-Whitney U test. Variables with a p-value of ≤0.1 in univariate analysis were fitted to perform logistic regression analysis to identify independent risk factors associated with VRE infection occurrence.
Results
A total of 229 children were admitted to the hematology/ oncology ward. Fecal VRE-C was documented in 72 of these patients (31.4%). Excluding eight patients who were transferred from the pediatric intensive care unit, 89% of the patients were colonized during their stay in the hematology/oncology ward. Species determination could be performed in 32 VRE-colonized patients: Enterococcus faecium was isolated in 28 patients, Enterococcus gallinarum in 2 patients, and nontypeable Enterococcus in 2 patients.
VRE-I was detected in 7 patients, all of whom were previously colonized with VRE. The overall rate of VRE-I developing in patients with VRE-C was 9.7%. VRE bacteremia was detected in five patients (6.9%). Other VRE infections were urinary Table 2 . Four out of seven patients were receiving a glycopeptide antibiotic when a systemic VRE infection was diagnosed. Multivariate analysis revealed severe neutropenia and history of previous bacteremia with another pathogen as independent risk factors for development of VRE infection in a VRE-colonized patient with cancer (Table 3 ).
All VRE infections were treated with linezolid. No VREattributable deaths occurred during systemic VRE infections. However, crude mortality was higher in patients who suffered from VRE infection than those who did not (2/7 (28.6%) vs. 4/65 (6.2%), respectively; p=0.04).
Discussion
Overall, 31.4% of patients admitted to our hematology/oncology ward were colonized with VRE. Colonization rates in other studies ranged from 4.7% to 38% [4, 5, 6, 7] . Systemic VRE infections develop mostly in VRE-colonized patients [8, 9] , although some contrary cases may exist rarely [5, 10] . In this study, about 1 in 10 VRE-colonized patients developed subsequent systemic VRE infection (9.7%). Studies evaluating cancer patients reported a range of 13% to 61% rate of progression of VRE colonization to VRE bacteremia [6, 10, 11, 12, 13] .
Results of univariate analysis revealed some risk factors associated with VRE-I development. One of them was severe neutropenia (<100/mm 3 ) and longer duration of neutropenia, which was consistent with the literature [4, 7, 12, 13] . The presence and a longer duration of total parenteral nutritional support were more likely to be present in VRE-I patients. It increases the risk of infection due to the use of an invasive central line, tendency for a longer hospitalization, and disadvantageous effects on gastrointestinal flora [14, 15] . Its association with VRE infection in our univariate analysis may merely indicate illness severity of the patients, which is the main predisposing factor for VRE bacteremia [10, 16] . In casecontrol studies, colonization and infection with VRE have been associated with exposure to several antibiotics, especially to glycopeptides [8, 17] . In the current study, VRE-I patients had longer duration of glycopeptide treatment and more frequently received glycopeptides after detection of VRE colonization, similar to literature findings [7, 10, 13] . After multivariate analysis, severe neutropenia and history of previous bacteremia with another pathogen remained as independent risk factors for development of VRE infection in a colonized patient. Previous bacteremia episodes were not evaluated in similar reports. It may be proposed that a previous blood stream infection history indicates the patient's severity of illness, which in turn increases the risk of a VRE infection. Moreover, a bacteremia episode itself might have caused clinical deterioration of the patients, predisposing them to the progression of VRE colonization to a systemic infection.
It was reported that active screening leads to reduced VRE colonization, infection, and reduced costs [18] . In a comparative 
